At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating ...

People aged 80 and older with a common type of lymphoma can take a half-dose of chemotherapy and be cured or significantly ...

In this video, Brian T. Hill, MD, PhD, discusses a study presented at ASH Annual Meeting and Exposition which assessed a triplet nonchemotherapy regimen in older and medically unfit patients with ...

A 2025 report cowritten by Iyengar that quoted federal data, said that the 5-year DLBCL survival is approximately 80% in ...

Doctors may not need to avoid steroids before biopsy in patients with a common aggressive lymphoma, according to a new study.

This was a study led by Dr. Pallawi Torka from Memorial Sloan Kettering that we participated in, where they performed as a ...

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL.

In this video, Brian T. Hill, MD, PhD, discusses promising results from a study examining the impact of acalabrutinib prior to frontline chemotherapy in patients with untreated diffuse large B-cell ...

Epkinly combined with GemOx achieved durable remissions in relapsed/refractory DLBCL, addressing unmet needs in second-line ...

Zanubrutinib combined with R-CHOP showed high efficacy in DLBCL patients with activated BCR signaling and specific genetic mutations, achieving a 91.4% ORR and 79.3% CR rate. The study's primary ...

The researchers argue that their findings, published in Scientific Reports, could help clinicians anticipate which patients ...